Based on the information available, it is difficult to make a definitive statement regarding whether or not Lipitor is still necessary for treatment without considering specific medical circumstances. Lipitor, the brand name for atorvastatin, is a medication used to treat high cholesterol and reduce the risk of stroke and heart attack [1].
The patent for Lipitor expired in 2011, which led to the introduction of generic atorvastatin to the market [2]. With the availability of generic alternatives, the cost of treatment has significantly decreased, making atorvastatin more accessible to patients [3].
The decision to use Lipitor or its generic counterparts should be based on an individual's medical history, current health status, potential side effects, and the patient's response to treatment [1]. It is essential to consult with a healthcare professional to determine the most appropriate course of action.
In some cases, patients may continue to use Lipitor if they have experienced positive results and have no issues with the brand-name drug's cost or insurance coverage [4]. However, generic atorvastatin is generally recommended as a cost-effective and therapeutically equivalent alternative [5].
In summary, while Lipitor can still be a necessary treatment for some individuals, generic atorvastatin is a more accessible and affordable option for most patients, offering the same therapeutic benefits [1][2][3]. Consult with a healthcare professional to determine the most suitable cholesterol-lowering medication for each individual's needs.
Sources:
1. Mayo Clinic. (2021). Atorvastatin (Oral Route) - Mayo Clinic. Mayo Clinic. <https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/description/drg-20063095>.
2. DrugPatentWatch. (2021). Lipitor (Atorvastatin) Drug Patent Expiration and Generic Entry. DrugPatentWatch. <https://www.drugpatentwatch.com/drugs/lipitor>.
3. FDA. (2012). FDA approves first generic of Lipitor to compete in the marketplace. U.S. Food and Drug Administration. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-lipitor-compete-marketplace>.
4. Gagnon, M. A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS medicine, 5(1), e1. <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050001>.
5. StatPearls. (2021). Atorvastatin. StatPearls [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK519505/>.